Literature DB >> 16631755

Protein kinase PKC delta and c-Abl are required for mitochondrial apoptosis induction by genotoxic stress in the absence of p53, p73 and Fas receptor.

Malika Lasfer1, Lise Davenne, Nathalie Vadrot, Catherine Alexia, Zahia Sadji-Ouatas, Annie-France Bringuier, Gérard Feldmann, Dominique Pessayre, Florence Reyl-Desmars.   

Abstract

Doxorubicin, cis-diamminedichloroplatinum (II) and 5-fluorouracil used in chemotherapy induce apoptosis in Hep3B cells in the absence of p53, p73, and functional Fas. Since mediators remain unknown, the requirement of PKC delta (PKCdelta) and c-Abl was investigated. Suppression of c-Abl or PKCdelta expression using SiRNAs impaired PARP cleavage, Gleevec and/or rottlerin inhibited the induction of the subG1 phase and the increase of reactive oxygen species level. Co-precipitations and phosphorylations to mitochondria of c-Abl, PKCdelta and Bcl-X(L/s) were induced. A depolarization of the mitochondrial membrane and activations of caspase-2 and -9 were observed. We propose that, in the absence of p53, p73 and Fas, genotoxic drugs could require both PKCdelta and c-Abl to induce apoptosis through the mitochondrial pathway.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16631755     DOI: 10.1016/j.febslet.2006.03.089

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  17 in total

Review 1.  The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis.

Authors:  Yoshihide Asano; Andreea M Bujor; Maria Trojanowska
Journal:  J Dermatol Sci       Date:  2010-07-03       Impact factor: 4.563

2.  c-Abl silencing reduced the inhibitory effects of TGF-β1 on apoptosis in systemic sclerosis dermal fibroblasts.

Authors:  Elham Karimizadeh; Farhad Gharibdoost; Nasrin Motamed; Saeideh Jafarinejad-Farsangi; Ahmadreza Jamshidi; Mahdi Mahmoudi
Journal:  Mol Cell Biochem       Date:  2015-04-16       Impact factor: 3.396

3.  Inhibiting tyrosine phosphorylation of protein kinase Cδ (PKCδ) protects the salivary gland from radiation damage.

Authors:  Sten M Wie; Tariq S Adwan; James DeGregori; Steven M Anderson; Mary E Reyland
Journal:  J Biol Chem       Date:  2014-02-25       Impact factor: 5.157

Review 4.  Multifunctional roles of PKCδ: Opportunities for targeted therapy in human disease.

Authors:  Mary E Reyland; David N M Jones
Journal:  Pharmacol Ther       Date:  2016-05-11       Impact factor: 12.310

5.  Tyrosine 311 is phosphorylated by c-Abl and promotes the apoptotic effect of PKCdelta in glioma cells.

Authors:  Wei Lu; Susan Finnis; Cunli Xiang; Hae Kyung Lee; Yael Markowitz; Hana Okhrimenko; Chaya Brodie
Journal:  Biochem Biophys Res Commun       Date:  2006-11-16       Impact factor: 3.575

6.  Cisplatin-induced apoptosis in p53-deficient renal cells via the intrinsic mitochondrial pathway.

Authors:  Man Jiang; Cong-Yi Wang; Shuang Huang; Tianxin Yang; Zheng Dong
Journal:  Am J Physiol Renal Physiol       Date:  2009-03-11

7.  Protein kinase Cdelta negatively regulates hedgehog signaling by inhibition of Gli1 activity.

Authors:  Qingsong Cai; Jing Li; Tianyan Gao; Jingwu Xie; B Mark Evers
Journal:  J Biol Chem       Date:  2008-11-17       Impact factor: 5.157

Review 8.  Targeting malignant mitochondria with therapeutic peptides.

Authors:  Jonathan E Constance; Carol S Lim
Journal:  Ther Deliv       Date:  2012-08

9.  Receptor tyrosine kinase ErbB2 translocates into mitochondria and regulates cellular metabolism.

Authors:  Yan Ding; Zixing Liu; Shruti Desai; Yuhua Zhao; Hao Liu; Lewis K Pannell; Hong Yi; Elizabeth R Wright; Laurie B Owen; Windy Dean-Colomb; Oystein Fodstad; Jianrong Lu; Susan P LeDoux; Glenn L Wilson; Ming Tan
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

10.  Mitochondrial DNA maintenance is regulated in human hepatoma cells by glycogen synthase kinase 3β and p53 in response to tumor necrosis factor α.

Authors:  Nathalie Vadrot; Sarita Ghanem; Françoise Braut; Laura Gavrilescu; Nathalie Pilard; Abdellah Mansouri; Richard Moreau; Florence Reyl-Desmars
Journal:  PLoS One       Date:  2012-07-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.